The Role of IL-23 Inhibitors in Crohn's Disease

被引：14

作者：

Fanizza, Jacopo ^{[1
]}

D'Amico, Ferdinando ^{[1
,2
]}

Lusetti, Francesca ^{[1
,3
]}

Fasulo, Ernesto ^{[1
]}

Allocca, Mariangela ^{[1
]}

Furfaro, Federica ^{[1
]}

Zilli, Alessandra ^{[1
]}

Parigi, Tommaso Lorenzo ^{[1
]}

Radice, Simona ^{[1
]}

Peyrin-Biroulet, Laurent ^{[4
,5
,6
,7
,8
,9
]}

Danese, Silvio ^{[1
]}

Fiorino, Gionata ^{[1
,10
]}

机构：

[1] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Dept Gastroenterol & Endoscopy, I-20132 Milan, Italy

[2] Humanitas Univ, Dept Biomed Sci, I-20089 Milan, Italy

[3] Univ Pavia, Dept Gastroenterol, IRCCS Policlin San Matteo, I-27100 Pavia, Italy

[4] Nancy Univ Hosp, Dept Gastroenterol, F-54500 Vanoeuvre Les Nancy, France

[5] Univ Lorraine, Inserm, NGERE, F-54000 Nancy, France

[6] Nancy Univ Hosp, INFINY Inst, F-54500 Vandoevre Les Nancy, France

[7] Nancy Univ Hosp, FHU CURE, F-54500 Vanoeuvre Les Nancy, France

[8] Paris IBD Ctr, Grp Hosp Pr Ambroise Pare Hartmann, F-92200 Neuilly Sur Seine, France

[9] McGill Univ, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ H4A 3J1, Canada

[10] San Camillo Forlanini Hosp, Dept Gastroenterol & Digest Endoscopy, IBD Unit, I-00152 Rome, Italy

来源：

JOURNAL OF CLINICAL MEDICINE | 2024年 / 13卷 / 01期

关键词：

inflammatory bowel disease; Crohn's disease; IL-23; inhibitors; risankizumab; guselkumab; mirikizumab; brazikumab; MAINTENANCE THERAPY; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CYTOKINE; USTEKINUMAB; RISANKIZUMAB; INDUCTION; MODERATE; INTERLEUKIN-12; PROTEIN;

D O I：

10.3390/jcm13010224

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-12/23, is currently approved for the treatment of IBD in patients with disease refractory to corticosteroids and biologic drugs. Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn's disease (CD). However, only risankizumab currently has been approved for its treatment. Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results. In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD.

引用

页数：19

共 76 条

[51]

ncbi.nlm.nih, IL-12 and IL-23 Cytokines: From Discovery to Targeted Therapies for Immune-Mediated Inflammatory Diseases

[52] Personalised medicine in Crohn's disease [J].

Noor, Nurulamin M. ;

Verstockt, Bram ;

Parkes, Miles ;

Lee, James C. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (01) :80-92

[53] Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 [J].

Oppmann, B ;

Lesley, R ;

Blom, B ;

Timans, JC ;

Xu, YM ;

Hunte, B ;

Vega, F ;

Yu, N ;

Wang, J ;

Singh, K ;

Zonin, F ;

Vaisberg, E ;

Churakova, T ;

Liu, MR ;

Gorman, D ;

Wagner, J ;

Zurawski, S ;

Liu, YJ ;

Abrams, JS ;

Moore, KW ;

Rennick, D ;

de Waal-Malefyt, R ;

Hannum, C ;

Bazan, JF ;

Kastelein, RA .

IMMUNITY, 2000, 13 (05) :715-725

[54] Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis [J].

Papp, Kim A. ;

Blauvelt, Andrew ;

Bukhalo, Michael ;

Gooderham, Melinda ;

Krueger, James ;

Lacour, Jean-Philippe ;

Menter, Alan ;

Philipp, Sandra ;

Sofen, Howard ;

Tyring, Stephen ;

Berner, Beate R. ;

Visvanathan, Sudha ;

Pamulapati, Chandrasena ;

Bennett, Nathan ;

Flack, Mary ;

Scholl, Paul ;

Padula, Steven J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (16) :1551-1560

[55] A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R [J].

Parham, C ;

Chirica, M ;

Timans, J ;

Vaisberg, E ;

Travis, M ;

Cheung, J ;

Pflanz, S ;

Zhang, R ;

Singh, KP ;

Vega, F ;

To, W ;

Wagner, J ;

O'Farrell, AM ;

McClanahan, T ;

Zurawski, S ;

Hannum, C ;

Gorman, D ;

Rennick, DM ;

Kastelein, RA ;

Malefyt, RD ;

Moore, KW .

JOURNAL OF IMMUNOLOGY, 2002, 168 (11) :5699-5708

[56] Blockade of IL-23: What is in the Pipeline? [J].

Parigi, Tommaso Lorenzo ;

Iacucci, Marietta ;

Ghosh, Subrata .

JOURNAL OF CROHNS & COLITIS, 2022, 16 (SUPPL 2) :II64-II72

[57] IL-27, a heterodimeric cytokine composed of EB13 and p28 protein, induces proliferation of naive CD4+ T cells [J].

Pflanz, S ;

Timans, JC ;

Cheung, J ;

Rosales, R ;

Kanzler, H ;

Gilbert, J ;

Hibbert, L ;

Churakova, T ;

Travis, M ;

Vaisberg, E ;

Blumenschein, WM ;

Mattson, JD ;

Wagner, JL ;

To, W ;

Zurawski, S ;

McClanahan, TK ;

Gorman, DM ;

Bazan, JF ;

Malefyt, RD ;

Rennick, D ;

Kastelein, RA .

IMMUNITY, 2002, 16 (06) :779-790

[58] A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits [J].

Presky, DH ;

Yang, H ;

Minetti, LJ ;

Chua, AO ;

Nabavi, N ;

Wu, CY ;

Gately, MK ;

Gubler, U .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (24) :14002-14007

[59] ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment [J].

Raine, Tim ;

Bonovas, Stefanos ;

Burisch, Johan ;

Kucharzik, Torsten ;

Adamina, Michel ;

Annese, Vito ;

Bachmann, Oliver ;

Bettenworth, Dominik ;

Chaparro, Maria ;

Czuber-Dochan, Wladyslawa ;

Eder, Piotr ;

Ellul, Pierre ;

Fidalgo, Catarina ;

Fiorino, Gionata ;

Gionchetti, Paolo ;

Gisbert, Javier P. ;

Gordon, Hannah ;

Hedin, Charlotte ;

Holubar, Stefan ;

Iacucci, Marietta ;

Karmiris, Konstantinos ;

Katsanos, Konstantinos ;

Kopylov, Uri ;

Lakatos, Peter L. ;

Lytras, Theodore ;

Lyutakov, Ivan ;

Noor, Nurulamin ;

Pellino, Gianluca ;

Piovani, Daniele ;

Savarino, Edoardo ;

Selvaggi, Francesco ;

Verstockt, Bram ;

Spinelli, Antonino ;

Panis, Yves ;

Doherty, Glen .

JOURNAL OF CROHNS & COLITIS, 2022, 16 (01) :2-17

[60] Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice [J].

Ruggiero, A. ;

Fabbrocini, G. ;

Cinelli, E. ;

Garza, S. S. Ocampo ;

Camela, E. ;

Megna, M. .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (03) :561-567

← 1 2 3 4 5 6 7 8 →